Michael Gilman, Ph.D.

Michael Gilman, Ph.D., is a scientist, general manager, biotech executive and serial entrepreneur. Dr. Gillman is currently Chairman and Chief Executive Officer of Arrakis Therapeutics. He is a member of the Board of Directors of Scholar Rock and the Novartis Venture Fund and of the Scientific Advisory Board of FutuRx, a biotech accelerator in Israel. Previously, he served as Chief Executive Officer of Obsidian Therapeutics. He was Founder and Chief Executive Officer of Padlock Therapeutics, a venture-funded company focused on autoimmune disease, acquired by Bristol-Myers Squibb in 2016. Prior to Padlock, Dr. Gillman served as Senior Vice President, Early-Stage Pipeline, at Biogen Idec, with responsibility for managing the company’s development programs through clinical proof-of-concept. He joined Biogen Idec in March 2012 following its acquisition of Stromedix, a venture-backed company focused on fibrosis and organ failure, where he was Founder and Chief Executive Officer. Prior to founding Stromedix in 2006, Dr. Gillman served as Executive Vice President, Research at Biogen Idec, with responsibility for the company’s discovery research activities in Cambridge and San Diego. From 1994 to 1999, he was at ARIAD Pharmaceuticals, where he was Executive Vice President and Chief Scientific Officer. From 1986 to 1994, he was on the scientific staff of Cold Spring Harbor Laboratory in New York, where his research focused on mechanisms of signal transduction and gene regulation. Dr. Gillman was a postdoctoral fellow with Dr. Robert Weinberg at the Whitehead Institute. He holds a Ph.D. in biochemistry from University of California, Berkeley, and a S.B. in life sciences from Massachusetts Institute of Technology.